778 related articles for article (PubMed ID: 24229770)
21. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
Davidson MH; Beam CA; Haffner S; Perez A; D'Agostino R; Mazzone T
Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1873-6. PubMed ID: 20576945
[TBL] [Abstract][Full Text] [Related]
22. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
23. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT).
Mehta NN; Torigian DA; Gelfand JM; Saboury B; Alavi A
J Vis Exp; 2012 May; (63):e3777. PubMed ID: 22588186
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina.
Rogers IS; Nasir K; Figueroa AL; Cury RC; Hoffmann U; Vermylen DA; Brady TJ; Tawakol A
JACC Cardiovasc Imaging; 2010 Apr; 3(4):388-97. PubMed ID: 20394901
[TBL] [Abstract][Full Text] [Related]
25. Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography-Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes.
de Boer SA; Hovinga-de Boer MC; Heerspink HJ; Lefrandt JD; van Roon AM; Lutgers HL; Glaudemans AW; Kamphuisen PW; Slart RH; Mulder DJ
Diabetes Care; 2016 Aug; 39(8):1440-7. PubMed ID: 27281773
[TBL] [Abstract][Full Text] [Related]
26. Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Tawakol A; Finn AV
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1119-22. PubMed ID: 21999872
[No Abstract] [Full Text] [Related]
27. Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography.
Zhang MD; Zhao XC; Zhang YH; Yan YF; Wang ZM; Lv SZ; Zhao QM
Cardiovasc Ther; 2015 Jun; 33(3):118-26. PubMed ID: 25825053
[TBL] [Abstract][Full Text] [Related]
28. Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Marwick TH; Narula J
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1146-7. PubMed ID: 21999880
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
30. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study.
Bucerius J; Duivenvoorden R; Mani V; Moncrieff C; Rudd JH; Calcagno C; Machac J; Fuster V; Farkouh ME; Fayad ZA
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1195-205. PubMed ID: 22093271
[TBL] [Abstract][Full Text] [Related]
33. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
Tahara N; Yamagishi S; Mizoguchi M; Tahara A; Imaizumi T
Rejuvenation Res; 2013 Oct; 16(5):344-51. PubMed ID: 23777507
[TBL] [Abstract][Full Text] [Related]
35. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
36. Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study.
Valenzuela-Garcia LF; Matsuzawa Y; Sara JD; Kwon TG; Lennon RJ; Lerman LO; Ruiz-Salmeron RJ; Lerman A
Cardiovasc Diabetol; 2015 Aug; 14():106. PubMed ID: 26268857
[TBL] [Abstract][Full Text] [Related]
37. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake.
Bucerius J; Mani V; Moncrieff C; Rudd JH; Machac J; Fuster V; Farkouh ME; Fayad ZA
J Am Coll Cardiol; 2012 Jun; 59(23):2080-8. PubMed ID: 22651864
[TBL] [Abstract][Full Text] [Related]
38. Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.
Moon JH; Kim HJ; Kim SK; Kang ES; Lee BW; Ahn CW; Lee HC; Cha BS
Metabolism; 2011 Feb; 60(2):165-72. PubMed ID: 20092860
[TBL] [Abstract][Full Text] [Related]
39. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study.
Rudd JH; Myers KS; Bansilal S; Machac J; Woodward M; Fuster V; Farkouh ME; Fayad ZA
Circ Cardiovasc Imaging; 2009 Mar; 2(2):107-15. PubMed ID: 19808576
[TBL] [Abstract][Full Text] [Related]
40. Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT.
Hetterich H; Rominger A; Walter L; Habs M; Volpers S; Hacker M; Reiser MF; Bartenstein P; Saam T
Int J Cardiovasc Imaging; 2016 Jan; 32(1):49-59. PubMed ID: 25898891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
